Mihael H. Polymeropoulos - Nov 30, 2021 Form 4 Insider Report for Vanda Pharmaceuticals Inc. (VNDA)

Role
President and CEO, Director
Signature
/s/ Mihael Polymeropoulos
Stock symbol
VNDA
Transactions as of
Nov 30, 2021
Transactions value $
-$831,623
Form type
4
Date filed
12/2/2021, 03:31 PM
Next filing
Mar 2, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VNDA Common Stock Options Exercise $382K +78.3K +6.41% $4.88 1.3M Nov 30, 2021 Direct
transaction VNDA Common Stock Sale -$824K -50K -3.85% $16.49 1.25M Nov 30, 2021 Direct F1, F2
transaction VNDA Common Stock Options Exercise $350K +71.7K +5.74% $4.88 1.32M Dec 1, 2021 Direct
transaction VNDA Common Stock Sale -$739K -46.2K -3.5% $16.00 1.27M Dec 1, 2021 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VNDA Employee Stock Option (Right to Buy) Options Exercise $0 -78.3K -52.22% $0.00 71.7K Nov 30, 2021 Common Stock 78.3K $4.88 Direct F4
transaction VNDA Employee Stock Option (Right to Buy) Options Exercise $0 -71.7K -100% $0.00* 0 Dec 1, 2021 Common Stock 71.7K $4.88 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares of the Issuer's common stock sold to satisfy the exercise price and certain tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the exercise of certain stock options, which were scheduled to expire December 5, 2021 as reflected in this Form 4.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.10 to $16.96, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.70 to $16.41, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.
F4 The option vested in 48 equal monthly installments beginning on January 6, 2012.